To investigate the effects of integrative Traditional Chinese Medicine (TCM) and Western Medicine cancer treatment regimen's impact on survival time and rate，prognosis factors，and the suitable treatment group of elderly patients with advanced non-small cell lung cancer; and to provide a concrete reference for planning an individual's cancer treatment regimen. Methods:Retrospective analysis was used to analyze 74 cases of elderly patients with advanced non-small cell lung cancer in Longhua Hospital Oncology Department from January 2011 to December 2015; and the patients were divided into chemotherapy group (n=19)，traditional Chinese medicine (TCM) group (n=21)，and chemotherapy combined with traditional Chinese medicine (n=34). Results:The median survival time of TCM，chemotherapy and the combined group were 761 days，521 days and 769 days respectively. The median progression free survival time was 239 days，195 days and 245 days respectively (P>0.05). In addition，1-year survival rate are 89%，67% and 67% respectively; 3-year survival rates were 27%，16% and 37% respectively; and 5-year survival rates were 9%，0%，and 17% respectively. Moreover，the univariable analysis showed receiving TCM intravenously 8 treatments or orally 6 months (P<0.01，r=0.48)，targeted therapy time 1 year (P<0.01，r=0.33)，comorbidity (P<0.01，r=-0.28) are the prognosis factors. After stratifying both targeted therapy and chemotherapy data，we still found TCM intervention played an important prognosis impact factor. Multivariate analysis also concluded that TCM intervention (OR=0.09) and targeted therapy (OR=0.15) were the independent prognosis factors. Conclusion:Elderly patients with advanced non-small cell lung cancer can benefit from receiving the integrative Traditional Chinese Medicine and Western Medicine cancer treatment regimen.